Trials / Unknown
UnknownNCT05995808
Cyclin D1 as a Prognostic Factor in Multiple Myeloma and Its Association With the Immunological Prognostic Factor PDL1 and Clinical and Biochemical Lab Tests
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Sohag University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Multiple myeloma (MM) is the most common bone marrow malignancy of terminally differentiated plasma cells. It accounts for about 1% of all malignant diseases and 10% of haematological malignancies and takes the second place after non-Hodgkin lymphoma . There are some serological and clinical criteria that help to detect the stage of MM and predict the patients' prognosis. These criteria include the level of M protein, calcium, haemoglobin, albumin, creatinine, β2-microglobulin and glomerular filtration rate (GFR).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Bone marow biopsy and aspiration | Bone marrow biopsy and biopsy aspiration |
| DIAGNOSTIC_TEST | biochemical and heamatological tests | complete blood count ,serum urea and creatinine |
Timeline
- Start date
- 2023-09-01
- Primary completion
- 2024-08-01
- Completion
- 2025-08-01
- First posted
- 2023-08-16
- Last updated
- 2023-08-16
Source: ClinicalTrials.gov record NCT05995808. Inclusion in this directory is not an endorsement.